基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
賽多酷力特斯公司是一家處於後期階段的生物製藥公司,專注於發現、開發和商業化肌肉激活劑和抑制劑,作為治療虛弱性疾病的潛在療法。該公司主要開發小分子藥物候選物,旨在影響肌肉功能和收縮。其藥物候選物包括:
1. 奧美卡替布,一種新型心肌肌球蛋白激活劑,正處於III期臨床試驗階段,用於治療心力衰竭患者。
2. 瑞德賽米特,一種骨骼肌肌鈣調蛋白激活劑,正處於III期臨床試驗階段,用於治療肌萎縮性側索硬化症和脊髓性肌肉萎縮。
3. CK-136,一種新型心肌肌鈣調蛋白激活劑,正處於I期臨床試驗階段。
4. 阿非卡美汀,一種新型心肌肌球蛋白抑制劑,正處於III期臨床試驗階段,用於治療症狀性梗阻性肥厚型心肌病患者。
5. CK-3772271,一種小分子心肌肌球蛋白抑制劑,正處於I期臨床試驗階段。
賽多酷力特斯公司與Astellas Pharma Inc.有戰略聯盟。該公司成立於1997年,總部位於加州南舊金山。
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
